Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Arthritis Research & Therapy
Erschienen in: Arthritis Research & Therapy 4/2003

01.09.2003 | Commentary

SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus

verfasst von: Martin Aringer, Josef S Smolen

Erschienen in: Arthritis Research & Therapy | Ausgabe 4/2003

Einloggen, um Zugang zu erhalten

Abstract

Tumor necrosis factor (TNF) is a proinflammatory cytokine and a B-cell growth factor. It has numerous possible effects on T lymphocytes and dendritic cells, and it influences apoptosis. These differential effects may in part explain why patients under TNF-blocker therapy can develop autoantibodies to nuclear antigens, and may shed some light on the finding that low TNF fosters autoimmune disease in some mouse strains. On the contrary, TNF is increased in the blood and in the inflamed kidneys of systemic lupus erythematosus patients. Several studies in lupus-prone mice other than the F1 generation of New Zealand Black mice crossed with New Zealand White mice suggest that TNF is highly proinflammatory in the efferent limb and is potentially detrimental in lupus organ disease. Therefore, TNF blockade probably constitutes an efficacious therapeutic option.
Literatur
1.
Maury CP, Teppo AM: Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum. 1989, 32: 146-150.CrossRefPubMed
2.
Studnicka-Benke A, Steiner G, Petera P, Smolen JS: Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol. 1996, 35: 1067-1074. 10.1093/rheumatology/35.11.1067.CrossRefPubMed
3.
Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, Vischer T, Yazici H, Guerne PA: Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol. 1997, 24: 303-308.PubMed
4.
Aringer M, Stummvoll GH, Steiner G, Koller M, Steiner CW, Hofler E, Hiesberger H, Smolen JS, Graninger WB: Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology (Oxford). 2001, 40: 876-881. 10.1093/rheumatology/40.8.876.CrossRef
5.
Aringer M, Feierl E, Steiner G, Stummvoll GH, Höfler E, Steiner CW, Radda I, Smolen JS, Graninger WB: Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus. 2002, 11: 102-108. 10.1191/0961203302lu160oa.CrossRefPubMed
6.
Smolen J, Steiner G, Breedveld FC, Kalden JR, Lipsky PE, Maini RN: Anti-TNF therapy and drug induced lupus-like syndrome [abstract]. Ann Rheum Dis. 1999, 58 (suppl 1): 217-
7.
Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000, 43: 2383-2390. 10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.3.CO;2-4.CrossRefPubMed
8.
Mohan AK, Edwards ET, Cote TR, Siegel JN, Braun MM: Drug-induced systemic lupus erythematosus and TNF-alpha blockers [letter]. Lancet. 2002, 360: 646-10.1016/S0140-6736(02)09800-8.CrossRefPubMed
9.
Jacob CO, McDevitt HO: Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature. 1988, 331: 356-358. 10.1038/331356a0.CrossRefPubMed
10.
Kontoyiannis D, Kollias G: Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur J Immunol. 2000, 30: 2038-2047. 10.1002/1521-4141(200007)30:7<2038::AID-IMMU2038>3.0.CO;2-K.CrossRefPubMed
11.
Gordon C, Ranges GE, Greenspan JS, Wofsy D: Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol. 1989, 52: 421-434. 10.1016/0090-1229(89)90157-8.CrossRefPubMed
12.
Pisetsky DS: Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum. 2000, 43: 2381-2382. 10.1002/1529-0131(200011)43:11<2381::AID-ANR1>3.0.CO;2-M.CrossRefPubMed
13.
O'Shea JJ, Ma A, Lipsky P: Cytokines and autoimmunity. Nature Rev Immunol. 2002, 2: 37-45. 10.1038/nri702.CrossRef
14.
Mageed RA, Isenberg DA: Tumour necrosis factor alpha in systemic lupus erythematosus and anti-DNA autoantibody production. Lupus. 2002, 11: 850-855. 10.1191/0961203302lu306rr.CrossRefPubMed
15.
16.
Ettinger R, Mebius R, Browning JL, Michie SA, van Tuijl S, Kraal G, van Ewijk W, McDevitt HO: Effects of tumor necrosis factor and lymphotoxin on peripheral lymphoid tissue development. Int Immunol. 1998, 10: 727-741. 10.1093/intimm/10.6.727.CrossRefPubMed
17.
Jacob CO: Tumor necrosis factor alpha in autoimmunity: pretty girl or old witch?. Immunol Today. 1992, 13: 122-125. 10.1016/0167-5699(92)90107-I.CrossRefPubMed
18.
Wang Y, Wang J, Sun Y, Wu Q, Fu YX: Complementary effects of TNF and lymphotoxin on the formation of germinal center and follicular dendritic cells. J Immunol. 2001, 166: 330-337.CrossRefPubMed
19.
Ettinger R: The role of tumor necrosis factor and lymphotoxin in lymphoid organ development. Curr Top Microbiol Immunol. 2000, 251: 203-210.PubMed
20.
Fu YX, Chaplin DD: Development and maturation of secondary lymphoid tissues. Annu Rev Immunol. 1999, 17: 399-433. 10.1146/annurev.immunol.17.1.399.CrossRefPubMed
21.
Ruuls SR, Hoek RM, Ngo VN, McNeil T, Lucian LA, Janatpour MJ, Korner H, Scheerens H, Hessel EM, Cyster JG, McEvoy LM, Sedgwick JD: Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity. 2001, 15: 533-543. 10.1016/S1074-7613(01)00215-1.CrossRefPubMed
22.
Vinuesa CG, Cook MC: The molecular basis of lymphoid architecture and B cell responses: implications for immunodeficiency and immunopathology. Curr Mol Med. 2001, 1: 689-725. 10.2174/1566524013363276.CrossRefPubMed
23.
McDevitt H, Munson S, Ettinger R, Wu A: Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity. Arthritis Res. 2002, 4 (suppl 3): S141-S152. 10.1186/ar570.PubMedCentralCrossRefPubMed
24.
Kehrl JH, Miller A, Fauci AS: Effect of tumor necrosis factor alpha on mitogen-activated human B cells. J Exp Med. 1987, 166: 786-791. 10.1084/jem.166.3.786.CrossRefPubMed
25.
Boussiotis VA, Nadler LM, Strominger JL, Goldfeld AE: Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells. Proc Natl Acad Sci USA. 1994, 91: 7007-7011.PubMedCentralCrossRefPubMed
26.
Rieckmann P, Tuscano JM, Kehrl JH: Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in B-lymphocyte function. Methods. 1997, 11: 128-132. 10.1006/meth.1996.0396.CrossRefPubMed
27.
Mohan C, Shi Y, Laman JD, Datta SK: Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol. 1995, 154: 1470-1480.PubMed
28.
Early GS, Zhao W, Burns CM: Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black × New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol. 1996, 157: 3159-3164.PubMed
29.
Strand V: Monoclonal antibodies and other biologic therapies. Lupus. 2001, 10: 216-221. 10.1191/096120301669817290.CrossRefPubMed
30.
Griffiths B, Emery P: The treatment of lupus with cyclosporin A. Lupus. 2001, 10: 165-170. 10.1191/096120301672970034.CrossRefPubMed
31.
Fujii T, Okada M, Mimori T, Craft J: The transmembrane form of TNF-alpha drives autoantibody production in the absence of CD154: studies using MRL/Mp-Fas(lpr) mice. Clin Exp Immunol. 2002, 130: 224-232. 10.1046/j.1365-2249.2002.01982.x.PubMedCentralCrossRefPubMed
32.
Vanden Berghe W, Vermeulen L, De Wilde G, De Bosscher K, Boone E, Haegeman G: Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol. 2000, 60: 1185-1195. 10.1016/S0006-2952(00)00412-3.CrossRefPubMed
33.
Cross JT, Benton HP: The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Inflamm Res. 1999, 48: 255-261. 10.1007/s000110050456.CrossRefPubMed
34.
Diehl S, Rincon M: The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol. 2002, 39: 531-536. 10.1016/S0161-5890(02)00210-9.CrossRefPubMed
35.
Scheurich P, Thoma B, Ucer U, Pfizenmaier K: Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J Immunol. 1987, 138: 1786-1790.PubMed
36.
Zucali JR, Elfenbein GJ, Barth KC, Dinarello CA: Effects of human interleukin 1 and human tumor necrosis factor on human T lymphocyte colony formation. J Clin Invest. 1987, 80: 772-777.PubMedCentralCrossRefPubMed
37.
Yokota S, Geppert TD, Lipsky PE: Enhancement of antigen- and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor-alpha. J Immunol. 1988, 140: 531-536.PubMed
38.
Machold KP, Smolen JS: Interferon-gamma induced exacerbation of systemic lupus erythematosus. J Rheumatol. 1990, 17: 831-832.PubMed
39.
Graninger WB, Hassfeld W, Pesau BB, Machold KP, Zielinski CC, Smolen JS: Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. J Rheumatol. 1991, 18: 1621-1622.PubMed
40.
Theofilopoulos AN, Koundouris S, Kono DH, Lawson BR: The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res. 2001, 3: 136-141. 10.1186/ar290.PubMedCentralCrossRefPubMed
41.
Isomaki P, Panesar M, Annenkov A, Clark JM, Foxwell BM, Chernajovsky Y, Cope AP: Prolonged exposure of T cells to TNF down-regulates TCR zeta and expression of the TCR/CD3 complex at the cell surface. J Immunol. 2001, 166: 5495-5507.CrossRefPubMed
42.
43.
Menges M, Rossner S, Voigtlander C, Schindler H, Kukutsch NA, Bogdan C, Erb K, Schuler G, Lutz MB: Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med. 2002, 195: 15-21. 10.1084/jem.20011341.PubMedCentralCrossRefPubMed
44.
Palucka AK, Banchereau J, Blanco P, Pascual V: The interplay of dendritic cell subsets in systemic lupus erythematosus. Immunol Cell Biol. 2002, 80: 484-488. 10.1046/j.1440-1711.2002.01112.x.CrossRefPubMed
45.
Drakesmith H, Chain B, Beverley P: How can dendritic cells cause autoimmune disease?. Immunol Today. 2000, 21: 214-217. 10.1016/S0167-5699(00)01610-8.CrossRefPubMed
46.
Gill MA, Blanco P, Arce E, Pascual V, Banchereau J, Palucka AK: Blood dendritic cells and DC-poietins in systemic lupus erythematosus. Hum Immunol. 2002, 63: 1172-1180. 10.1016/S0198-8859(02)00756-5.CrossRefPubMed
47.
Scheinecker C, Zwolfer B, Koller M, Manner G, Smolen JS: Alterations of dendritic cells in systemic lupus erythematosus: phenotypic and functional deficiencies. Arthritis Rheum. 2001, 44: 856-865. 10.1002/1529-0131(200104)44:4<856::AID-ANR142>3.3.CO;2-1.CrossRefPubMed
48.
Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J: Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001, 294: 1540-1543. 10.1126/science.1064890.CrossRefPubMed
49.
Gary-Gouy H, Lebon P, Dalloul AH: Type I interferon production by plasmacytoid dendritic cells and monocytes is triggered by viruses, but the level of production is controlled by distinct cytokines. J Interferon Cytokine Res. 2002, 22: 653-659. 10.1089/10799900260100132.CrossRefPubMed
50.
Ishikawa S, Nagai S, Sato T, Akadegawa K, Yoneyama H, Zhang YY, Onai N, Matsushima K: Increased circulating CD11b+CD11c+ dendritic cells (DC) in aged BWF1 mice which can be matured by TNF-alpha into BLC/CXCL13-producing DC. Eur J Immunol. 2002, 32: 1881-1887. 10.1002/1521-4141(200207)32:7<1881::AID-IMMU1881>3.0.CO;2-Z.CrossRefPubMed
51.
Heller RA, Song K, Fan N, Chang DJ: The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell. 1992, 70: 47-56. 10.1016/0092-8674(92)90532-H.CrossRefPubMed
52.
Chan FK, Siegel RM, Lenardo MJ: Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity. 2000, 13: 419-422. 10.1016/S1074-7613(00)00041-8.CrossRefPubMed
53.
Karin M, Lin A: NF-kappaB at the crossroads of life and death. Nat Immunol. 2002, 3: 221-227. 10.1038/ni0302-221.CrossRefPubMed
54.
Chen G, Goeddel DV: TNF-R1 signaling: a beautiful pathway. Science. 2002, 296: 1634-1635. 10.1126/science.1071924.CrossRefPubMed
55.
Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS: NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998, 281: 1680-1683. 10.1126/science.281.5383.1680.CrossRefPubMed
56.
Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J: NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol. 2001, 21: 5299-5305. 10.1128/MCB.21.16.5299-5305.2001.PubMedCentralCrossRefPubMed
57.
Wu XC, Asselin E, Tsang BK: Nuclear factor kappaB-mediated induction of Flice-like inhibitory protein prevents tumor necrosis factor alpha-induced apoptosis in rat granulosa cells. Biol Reprod. 2002, 67: 436-441.CrossRef
58.
Ohshima S, Mima T, Sasai M, Nishioka K, Shimizu M, Murata N, Yoshikawa H, Nakanishi K, Suemura M, McCloskey RV, Kishimoto T, Saeki Y: Tumour necrosis factor alpha (TNF-alpha) interferes with Fas-mediated apoptotic cell death on rheumatoid arthritis (RA) synovial cells: a possible mechanism of rheumatoid synovial hyperplasia and a clinical benefit of anti-TNF-alpha therapy for RA. Cytokine. 2000, 12: 281-288. 10.1006/cyto.1999.0552.CrossRefPubMed
59.
Yamasaki S, Kawakami A, Nakashima T, Nakamura H, Kamachi M, Honda S, Hirai Y, Hida A, Ida H, Migita K, Kawabe Y, Koji T, Furuichi I, Aoyagi T, Eguchi K: Importance of NF-kappaB in rheumatoid synovial tissues: in situ NF-kappaB expression and in vitro study using cultured synovial cells. Ann Rheum Dis. 2001, 60: 678-684. 10.1136/ard.60.7.678.PubMedCentralCrossRefPubMed
60.
Schett G, Steiner CW, Groger M, Winkler S, Graninger W, Smolen J, Xu Q, Steiner G: Activation of Fas inhibits heat-induced activation of HSF1 and up-regulation of hsp70. FASEB J. 1999, 13: 833-842.PubMed
61.
Graninger WB, Steiner CW, Graninger MT, Aringer M, Smolen JS: Cytokine regulation of apoptosis and Bcl-2 expression in lymphocytes of patients with systemic lupus erythematosus. Cell Death Diff. 2000, 7: 966-972. 10.1038/sj.cdd.4400724.CrossRef
62.
Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992, 356: 314-317. 10.1038/356314a0.CrossRefPubMed
63.
Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S: Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 1994, 76: 969-976. 10.1016/0092-8674(94)90375-1.CrossRefPubMed
64.
Korner H, Cretney E, Wilhelm P, Kelly JM, Rollinghoff M, Sedgwick JD, Smyth MJ: Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype. J Exp Med. 2000, 191: 89-96. 10.1084/jem.191.1.89.PubMedCentralCrossRefPubMed
65.
Andreakos ET, Foxwell BM, Brennan FM, Maini RN, Feldmann M: Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev. 2002, 13: 299-313. 10.1016/S1359-6101(02)00018-7.CrossRefPubMed
66.
Boswell JM, Yui MA, Burt DW, Kelley VE: Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol. 1988, 141: 3050-3054.PubMed
67.
Yokoyama H, Kreft B, Kelley VR: Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms. Kidney Int. 1995, 47: 122-130.CrossRefPubMed
68.
Tsai CY, Wu TH, Huang SF, Sun KH, Hsieh SC, Han SH, Yu HS, Yu CL: Abnormal splenic and thymic IL-4 and TNF-alpha expression in MRL-lpr/lpr mice. Scand J Immunol. 1995, 41: 157-163.CrossRefPubMed
69.
Deguchi Y, Kishimoto S: Tumour necrosis factor/cachectin plays a key role in autoimmune pulmonary inflammation in lupus-prone mice. Clin Exp Immunol. 1991, 85: 392-395.PubMedCentralCrossRefPubMed
70.
Edwards CK, Zhou T, Zhang J, Baker TJ, De M, Long RE, Borcherding DR, Bowlin TL, Bluethmann H, Mountz JD: Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha. J Immunol. 1996, 157: 1758-1772.PubMed
71.
Su X, Zhou T, Yang P, Edwards CK, Mountz JD: Reduction of arthritis and pneumonitis in motheaten mice by soluble tumor necrosis factor receptor. Arthritis Rheum. 1998, 41: 139-149. 10.1002/1529-0131(199801)41:1<139::AID-ART17>3.3.CO;2-K.CrossRefPubMed
72.
Segal R, Dayan M, Zinger H, Mozes E: Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxiphylline. Lupus. 2001, 10: 23-31. 10.1191/096120301675275538.CrossRefPubMed
73.
Brennan DC, Yui MA, Wuthrich RP, Kelley VE: Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J Immunol. 1989, 143: 3470-3475.PubMed
74.
Nakamura T, Ebihara I, Fukui M, Osada S, Tomino Y, Masaki T, Goto K, Furuichi Y, Koide H: Renal expression of mRNAs for endothelin-1, endothelin-3 and endothelin receptors in NZB/W F1 mice. Ren Physiol Biochem. 1993, 16: 233-243.PubMed
75.
Debets JM, Van der Linden CJ, Dieteren IE, Leeuwenberg JF, Buurman WA: Fc-receptor cross-linking induces rapid secretion of tumor necrosis factor (cachectin) by human peripheral blood monocytes. J Immunol. 1988, 141: 1197-1201.PubMed
76.
Takemura T, Yoshioka K, Murakami K, Akano N, Okada M, Aya N, Maki S: Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch. 1994, 424: 459-464. 10.1007/BF00191429.CrossRefPubMed
77.
Malide D, Russo P, Bendayan M: Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol. 1995, 26: 558-564. 10.1016/0046-8177(95)90253-8.CrossRefPubMed
78.
Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtado R, Avalos-Diaz E: Renal expression of IL-6 and TNFalpha genes in lupus nephritis. Lupus. 1998, 7: 154-158. 10.1191/096120398678919949.CrossRefPubMed
79.
Aringer M, Zimmermann C, Graninger WB, Petera P, Steiner G, Ulrich W, Smolen JS: TNF is an essential mediator in lupus nephritis. Arthritis Rheum. 2002, 46: 3418-3419.
80.
Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, Ikuse T, Asano M, Iwakura Y: Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med. 2000, 191: 313-320. 10.1084/jem.191.2.313.PubMedCentralCrossRefPubMed
Metadaten
Titel
SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus
verfasst von
Martin Aringer
Josef S Smolen
Publikationsdatum
01.09.2003
Verlag
BioMed Central
Erschienen in
Arthritis Research & Therapy / Ausgabe 4/2003
Elektronische ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar770

Weitere Artikel der Ausgabe 4/2003

Arthritis Research & Therapy 4/2003 Zur Ausgabe

Commentary

SLE - Rituximab in lupus

Meeting report

Cytokines in systemic lupus erythematosus, London, UK

Article selection

Articles selected from Faculty of 1000 in July 2003

Research article

Regulation and localization of endogenous human tristetraprolin

Research article

DEK binding to class II MHC Y-box sequences is gene- and allele-specific

Research article

Upregulated hypoxia inducible factor-1α and -2α pathway in rheumatoid arthritis and osteoarthritis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise